Description: Hoth Therapeutics Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth intends to use the BioLexa Platform to develop two different topical cream products: (i) a product to treat eczema and (ii) a product that reduces post-procedure infections, accelerates healing and improves clinical outcomes for patients undergoing aesthetic dermatology procedures. Hoth’s initial focus will be on the development of the BioLexa Platform for the treatment of eczema. Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis.
Home Page: www.hoththerapeutics.com
HOTH Technical Analysis
1 Rockefeller Plaza
New York,
NY
10020
United States
Phone:
646 756 2997
Officers
| Name | Title |
|---|---|
| Mr. Robb Knie | Pres, CEO & Chairman |
| Ms. Jane H. Springer | VP of Operations |
| Dr. Stefanie Johns Ph.D. | Chief Scientific Officer |
| Mr. David S. Briones | Chief Financial Officer |
| Hayley Springer | Exec. VP of Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4802 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-02-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |